| 摘要 |
H"/dtRnICrWoVCn/NR onb/DCCMAR/6946970_ IdoCx-3/l/20I4 The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL- 17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof). |
